Loading...
PRPO logo

Precipio, Inc.NasdaqCM:PRPO Stock Report

Market Cap US$47.3m
Share Price
n/a
1Y52.8%
7D-5.8%
1D-10.1%
Portfolio Value
​
View

Precipio, Inc.

NasdaqCM:PRPO Stock Report

Market Cap: US$47.3m

Precipio (PRPO) Stock Overview

A healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. More details

PRPO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings have grown 32.9% per year over the past 5 years

Risk Analysis

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($47M)

Significant insider selling over the past 3 months


PRPO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW490,690 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
490,690 investors already sharing narratives
View all narratives

Precipio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Precipio
Historical stock prices
Current Share PriceUS$23.80
52 Week HighUS$33.63
52 Week LowUS$13.02
Beta1.28
1 Month Change5.54%
3 Month Change-12.66%
1 Year Change52.81%
3 Year Change247.95%
5 Year Change-60.47%
Change since IPO-99.12%

Recent News & Updates

Recent updates

Analysis Article • Nov 19

Precipio, Inc. (NASDAQ:PRPO) Stock Rockets 28% But Many Are Still Ignoring The Company

Precipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 28% gain in the last month alone. The...
Analysis Article • Sep 08

Precipio, Inc.'s (NASDAQ:PRPO) Shares Leap 28% Yet They're Still Not Telling The Full Story

Precipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 28% gain in the last month alone. The...
Seeking Alpha • Aug 07

Precipio: Cash Flow Positivity May Remove Going Concern Language

Summary Precipio is a microcap cancer diagnostics firm with proprietary assays and culture media, targeting a growing niche in hematologic oncology diagnostics. Recent cost controls, margin expansion, and MolDx Medicare approval position Precipio to achieve positive cash flow and remove 'going concern' audit language by early 2026. The company’s differentiated products, strong distribution partnerships, and disciplined management support multi-year revenue growth and margin expansion. Precipio trades at a deep discount to peers; successful execution could drive 2–4x upside as valuation re-rates with improved financials and institutional interest. Read the full article on Seeking Alpha
Analysis Article • Jul 12

Further Upside For Precipio, Inc. (NASDAQ:PRPO) Shares Could Introduce Price Risks After 41% Bounce

Precipio, Inc. ( NASDAQ:PRPO ) shares have continued their recent momentum with a 41% gain in the last month alone. The...
Analysis Article • Feb 20

Investors Still Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues Despite 28% Price Jump

Despite an already strong run, Precipio, Inc. ( NASDAQ:PRPO ) shares have been powering on, with a gain of 28% in the...
Analysis Article • Dec 20

Investors Aren't Entirely Convinced By Precipio, Inc.'s (NASDAQ:PRPO) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 0.5x Precipio, Inc. ( NASDAQ:PRPO ) is a stock worth...
Analysis Article • Aug 21

Market Might Still Lack Some Conviction On Precipio, Inc. (NASDAQ:PRPO) Even After 29% Share Price Boost

Precipio, Inc. ( NASDAQ:PRPO ) shareholders would be excited to see that the share price has had a great month, posting...
Analysis Article • Jun 07

Here's Why Shareholders May Want To Be Cautious With Increasing Precipio, Inc.'s (NASDAQ:PRPO) CEO Pay Packet

Key Insights Precipio will host its Annual General Meeting on 13th of June Total pay for CEO Ilan Danieli includes...
Analysis Article • Mar 29

Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

With a median price-to-sales (or "P/S") ratio of close to 1.1x in the Healthcare industry in the United States, you...
Analysis Article • Aug 29

Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity

It's not a stretch to say that Precipio, Inc.'s ( NASDAQ:PRPO ) price-to-sales (or "P/S") ratio of 0.9x right now seems...
Seeking Alpha • Jul 20

Precipio to distribute HemeScreen through Fisher Healthcare channel

Precipio (NASDAQ:PRPO) has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers. The Fisher Healthcare channel will enable Precipio to expand access to laboratories across the U.S. for Precipio’s HemeScreen suite of products. This partnership is a logical expansion of Precipio’s distribution strategy, the leveraging of industry leading sales channels rather than building its own sales force. “The HemeScreen technology excels in these areas and will support the Fisher Healthcare channel in its commitment to serve its customers.” said Keith Meadors, Precipio’s Senior VP of Products.
Analysis Article • Jun 12

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

In the past three years, the share price of Precipio, Inc. ( NASDAQ:PRPO ) has struggled to grow and now shareholders...

Shareholder Returns

PRPOUS HealthcareUS Market
7D-5.8%-0.4%0.7%
1Y52.8%31.5%20.6%

Return vs Industry: PRPO exceeded the US Healthcare industry which returned 31.7% over the past year.

Return vs Market: PRPO exceeded the US Market which returned 19.5% over the past year.

Price Volatility

Is PRPO's price volatile compared to industry and market?
PRPO volatility
PRPO Average Weekly Movement8.3%
Healthcare Industry Average Movement7.2%
Market Average Movement7.3%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: PRPO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PRPO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a66Ilan Danieliwww.precipiodx.com

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages.

Precipio, Inc. Fundamentals Summary

How do Precipio's earnings and revenue compare to its market cap?
PRPO fundamental statistics
Market capUS$47.33m
Earnings (TTM)-US$922.00k
Revenue (TTM)US$25.83m
1.6x
P/S Ratio
-46.1x
P/E Ratio

Is PRPO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRPO income statement (TTM)
RevenueUS$25.83m
Cost of RevenueUS$14.54m
Gross ProfitUS$11.29m
Other ExpensesUS$12.21m
Earnings-US$922.00k

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin43.71%
Net Profit Margin-3.57%
Debt/Equity Ratio0.5%

How did PRPO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 14:10
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Precipio, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Benjamin HaynorAlliance Global Partners
Jason McCarthyMaxim Group